Inhibitors of the acetylcholinesterase and butyrylcholinesterasehave been found to increase the level of acetylcholine in the brain, hence maintaining better management of symptoms in Alzheimer’s disease patients. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.